Vaccinex announced topline data from the early manifest treatment arm of the company’s Phase II SIGNAL trial of pepinemab in patients with early manifest and prodromal Huntington’s disease (HD).

AstraZeneca released new results from the company’s ADAURA Phase III trial showing that Tagrisso (osimertinib) demonstrated clinically meaningful improvement in central nervous system disease-free survival in the adjuvant treatment of patients with early-stage epidermal growth factor receptor-mutated non-small cell lung cancer (NSCLC), after complete tumor resection.

The U.S. Food and Drug Administration approved FoundationOne Liquid CDx, a new pan-tumor liquid biopsy test that is indicated for use as a companion diagnostic for four FDA-approved precision therapies.

August is a busy month on the U.S. Food and Drug Administration)’s calendar, including a target action date for Bristol Myers Squibb’s supplemental Biologics License Application for Opdivo (nivolumab) plus Yervoy (ipilimumab), dosed concomitantly with a limited course of chemotherapy, for the first-line treatment of metastatic or recurrent non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations.

AstraZeneca inked a global development and commercialization deal with Daiichi Sankyo for DS-1062, a trophoblast cell-surface antigen 2 (TROP2)-directed antibody drug conjugate for multiple cancer types.

Roche struck a $1.7 billion cancer drug pact with Blueprint Medicines, as advances in genetic testing for rare mutations drive lucrative deals for expensive treatments.

AstraZeneca released detailed data from the Phase III ADAURA clinical trial of Tagrisso (osimertinib) in early-stage epidermal growth factor receptor-mutated non-small cell lung cancer

The U.S. Food and Drug Administration approved Takeda Pharmaceutical Company Limited’s Alunbrig (brigatinib) for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.

The first treatment for adult patients with metastatic non-small cell lung cancer (NSCLC) who also have a specific genetic mutation was approved by the U.S. Food and Drug Administration.

Sanofi and Regeneron halted a Phase III study of the checkpoint inhibitor Libtayo (cemiplimab) as a monotherapy treatment for advanced or metastatic non-small cell lung cancer due to early signs of significant improvement in overall survival.